|
1
|
Balch C, Huang TH, Brown R and Nephew KP:
The epigenetics of ovarian cancer drug resistance and
resensitization. Am J Obstet Gynecol. 191:1552–1572. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
3
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson SW, Ozols RF and Hamilton TC:
Mechanisms of drug resistance in ovarian cancer. Cancer. 71(Suppl
2): S644–S649. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fraser M, Leung BM, Yan X, Dan HC, Cheng
JQ and Tsang BK: p53 is a determinant of X-linked inhibitor of
apoptosis protein/Akt-mediated chemoresistance in human ovarian
cancer cells. Cancer Res. 63:7081–7088. 2003.PubMed/NCBI
|
|
7
|
Cheng JQ, Jiang X, Fraser M, Li M, Dan HC,
Sun M and Tsang BK: Role of X-linked inhibitor of apoptosis protein
in chemoresistance in ovarian cancer: possible involvement of the
phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat.
5:131–146. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sager R: Tumor suppressor genes: the
puzzle and the promise. Science. 246:1406–1412. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sherr CJ: Principles of tumor suppression.
Cell. 116:235–246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shanker M, Jin J, Branch CD, Miyamoto S,
Grimm EA, Roth JA and Ramesh R: Tumor suppressor gene-based
nanotherapy: from test tube to the clinic. J Drug Deliv.
2011:4658452011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaur M, Radovanovic A, Essack M, et al:
Database for exploration of functional context of genes implicated
in ovarian cancer. Nucleic Acids Res. 37:D820–D823. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cancer Genome Atlas Research Network.
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar
|
|
13
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: new opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao M, Sun J and Zhao Z: Distinct and
competitive regulatory patterns of tumor suppressor genes and
oncogenes in ovarian cancer. PLoS One. 7:e441752012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen H, Hardy TM and Tollefsbol TO:
Epigenomics of ovarian cancer and its chemoprevention. Front Genet.
2:672011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matei D, Shen C, Fang F, et al: A phase II
study of decitabine and carboplatin in recurrent platinum
(Pt)-resistant ovarian cancer (OC). J Clin Oncol. 29(Suppl): abst
5011. 2011.
|
|
17
|
Yang D, Khan S, Sun Y, Hess K, Shmulevich
I, Sood AK and Zhang W: Association of BRCA1 and BRCA2 mutations
with survival, chemotherapy sensitivity, and gene mutator phenotype
in patients with ovarian cancer. JAMA. 306:1557–1565. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou C, Smith JL and Liu J: Role of BRCA1
in cellular resistance to paclitaxel and ionizing radiation in an
ovarian cancer cell line carrying a defective BRCA1. Oncogene.
22:2396–2404. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Borst P, Rottenberg S and Jonkers J: How
do real tumors become resistant to cisplatin? Cell Cycle.
7:1353–1359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Wiltshire T, Senft J, Reed E and
Wang W: Irofulven induces replication-dependent CHK2 activation
related to p53 status. Biochem Pharmacol. 73:469–480. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang P, Gao W, Li H, Reed E and Chen F:
Inducible degradation of checkpoint kinase 2 links to
cisplatin-induced resistance in ovarian cancer cells. Biochem
Biophys Res Commun. 328:567–572. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chou JL, Su HY, Chen LY, et al: Promoter
hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and
tumor suppressor, is associated with poor prognosis in human
ovarian cancer. Lab Invest. 90:414–425. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Plumb JA, Strathdee G, Sludden J, Kaye SB
and Brown R: Reversal of drug resistance in human tumor xenografts
by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene
promoter. Cancer Res. 60:6039–6044. 2000.
|
|
24
|
Strathdee G, MacKean MJ, Illand M and
Brown R: A role for methylation of the hMLH1 promoter in loss of
hMLH1 expression and drug resistance in ovarian cancer. Oncogene.
18:2335–2341. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Staub J, Chien J, Pan Y, et al: Epigenetic
silencing of HSulf-1 in ovarian cancer: implications in
chemoresistance. Oncogene. 26:4969–4978. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu P, Gou M, Yi T, et al: Efficient
inhibition of an intraperitoneal xenograft model of human ovarian
cancer by HSulf-1 gene delivered by biodegradable cationic
heparin-polyethyleneimine nanogels. Oncol Rep. 27:363–370.
2012.
|
|
27
|
Gopalan B, Shanker M, Scott A, Branch CD,
Chada S and Ramesh R: MDA-7/IL-24, a novel tumor
suppressor/cytokine is ubiquitinated and regulated by the
ubiquitin-proteasome system, and inhibition of MDA-7/IL-24
degradation enhances the antitumor activity. Cancer Gene Ther.
15:1–8. 2008. View Article : Google Scholar
|
|
28
|
Xiong J, Peng ZL and Tan X: Effects of
adenoviral-mediated mda-7/IL-24 gene infection on the growth and
drug-resistance of drug-resistant. Sichuan Da Xue Xue Bao Yi Xue
Ban. 38:433–436. 2007.(In Chinese).
|
|
29
|
Kawakami Y, Hama S, Hiura M, et al:
Adenovirus-mediated p16 gene transfer changes the sensitivity to
taxanes and Vinca alkaloids of human ovarian cancer cells.
Anticancer Res. 21:2537–2545. 2001.PubMed/NCBI
|
|
30
|
Takai N and Narahara H: Histone
deacetylase inhibitor therapy in epithelial ovarian cancer. J
Oncol. 2010:4584312010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xia X, Ma Q, Li X, et al: Cytoplasmic p21
is a potential predictor for cisplatin sensitivity in ovarian
cancer. BMC Cancer. 11:3992011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Materna V, Surowiak P, Markwitz E,
Spaczynski M, Drag-Zalesinska M, Zabel M and Lage H: Expression of
factors involved in regulation of DNA mismatch repair- and
apoptosis pathways in ovarian cancer patients. Oncol Rep.
17:505–516. 2007.PubMed/NCBI
|
|
33
|
Cao Z, Yoon JH, Nam SW, Lee JY and Park
WS: PDCD4 expression inversely correlated with miR-21 levels in
gastric cancers. J Cancer Res Clin Oncol. 138:611–619. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang X, Wang X, Song X, et al: Programmed
cell death 4 enhances chemosensitivity of ovarian cancer cells by
activating death receptor pathway in vitro and in vivo. Cancer Sci.
101:2163–2170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang H, Kong W, He L, et al: MicroRNA
expression profiling in human ovarian cancer: miR-214 induces cell
survival and cisplatin resistance by targeting PTEN. Cancer Res.
68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee S, Choi EJ, Jin C and Kim DH:
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA
amplification contributes to cisplatin resistance in an ovarian
cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu H, Cao Y, Weng D, et al: Effect of
tumor suppressor gene PTEN on the resistance to cisplatin in human
ovarian cancer cell lines and related mechanisms. Cancer Lett.
271:260–271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yan X, Fraser M, Qiu Q and Tsang BK:
Over-expression of PTEN sensitizes human ovarian cancer cells to
cisplatin-induced apoptosis in a p53-dependent manner. Gynecol
Oncol. 102:348–355. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kassler S, Donninger H, Birrer MJ and
Clark GJ: RASSF1A and the Taxol response in ovarian cancer. Mol
Biol Int. 2012:2632672012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chmelarova M, Krepinska E, Spacek J, Laco
J, Beranek M and Palicka V: Methylation in the p53 promoter in
epithelial ovarian cancer. Clin Transl Oncol. 15:160–162. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Reles A, Wen WH, Schmider A, et al:
Correlation of p53 mutations with resistance to platinum-based
chemotherapy and shortened survival in ovarian cancer. Clin Cancer
Res. 7:2984–2997. 2001.PubMed/NCBI
|
|
42
|
Zhang YL, Guo XR, Shen DH, Cheng YX, Liang
XD, Chen YX and Wang Y: Expression and promotor methylation of p73
gene in ovarian epithelial tumors. Zhonghua Bing Li Xue Za Zhi.
41:33–38. 2012.(In Chinese).
|
|
43
|
Al-Bahlani S, Fraser M, Wong AY, Sayan BS,
Bergeron R, Melino G and Tsang BK: P73 regulates cisplatin-induced
apoptosis in ovarian cancer cells via a calcium/calpain-dependent
mechanism. Oncogene. 30:4219–4230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang W, Cui S, Ma J, Lu Q, Kong C, Liu T
and Sun Z: Cigarette smoking extract causes hypermethylation and
inactivation of WWOX gene in T-24 human bladder cancer cells.
Neoplasma. 59:216–223. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu YY, Li L, Li DR, Zhang W and Wang Q:
Suppression of WWOX gene by RNA interference reverses platinum
resistance acquired in SKOV3/SB cells. Zhonghua Fu Chan Ke Za Zhi.
43:854–858. 2008.(In Chinese).
|
|
46
|
Sharan R, Ulitsky I and Shamir R:
Network-based prediction of protein function. Mol Syst Biol.
3:882007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mostafavi S, Ray D, Warde-Farley D,
Grouios C and Morris Q: GeneMANIA: a real-time multiple association
network integration algorithm for predicting gene function. Genome
Biol. 9(Suppl 1): S42008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huang X and Guo B: Adenomatous polyposis
coli determines sensitivity to histone deacetylase
inhibitor-induced apoptosis in colon cancer cells. Cancer Res.
66:9245–9251. 2006. View Article : Google Scholar
|
|
49
|
Ogawa T, Liggett TE, Melnikov AA, et al:
Methylation of death-associated protein kinase is associated with
cetuximab and erlotinib resistance. Cell Cycle. 11:1656–1663. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Berge EO, Knappskog S, Geisler S, et al:
Identification and characterization of retinoblastoma gene
mutations disturbing apoptosis in human breast cancers. Mol Cancer.
9:1732010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ramachandran K, Gordian E and Singal R:
5-azacytidine reverses drug resistance in bladder cancer cells.
Anticancer Res. 31:3757–3766. 2011.PubMed/NCBI
|
|
52
|
Ramachandran K, Miller H, Gordian E,
Rocha-Lima C and Singal R: Methylation-mediated silencing of TMS1
in pancreatic cancer and its potential contribution to
chemosensitivity. Anticancer Res. 30:3919–3925. 2010.PubMed/NCBI
|
|
53
|
Tomkova K, Tomka M and Zajac V:
Contribution of p53, p63, and p73 to the developmental diseases and
cancer. Neoplasma. 55:177–181. 2008.PubMed/NCBI
|
|
54
|
Lo Nigro C, Monteverde M, Riba M, et al:
Expression profiling and long lasting responses to chemotherapy in
metastatic gastric cancer. Int J Oncol. 37:1219–1228.
2010.PubMed/NCBI
|
|
55
|
Zhang X, Gu L, Li J, et al: Degradation of
MDM2 by the interaction between berberine and DAXX leads to potent
apoptosis in MDM2-overexpressing cancer cells. Cancer Res.
70:9895–9904. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Poyurovsky MV, Katz C, Laptenko O, et al:
The C terminus of p53 binds the N-terminal domain of MDM2. Nat
Struct Mol Biol. 17:982–989. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mir R, Tortosa A, Martinez-Soler F, et al:
Mdm2 antagonists induce apoptosis and synergize with cisplatin
overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Int J Cancer. 132:1525–1536. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kanayama H, Tanaka K, Aki M, et al:
Changes in expressions of proteasome and ubiquitin genes in human
renal cancer cells. Cancer Res. 51:6677–6685. 1991.PubMed/NCBI
|
|
59
|
Jiang RD, Zhang LX, Yue W, et al:
Establishment of a human nasopharyngeal carcinoma drug-resistant
cell line CNE2/DDP and screening of drug-resistant genes. Ai Zheng.
22:337–345. 2003.(In Chinese).
|
|
60
|
Jenssen TK, Laegreid A, Komorowski J and
Hovig E: A literature network of human genes for high-throughput
analysis of gene expression. Nat Genet. 28:21–28. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Casorelli I, Bossa C and Bignami M: DNA
damage and repair in human cancer: molecular mechanisms and
contribution to therapy-related leukemias. Int J Environ Res Public
Health. 9:2636–2657. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li J, Feng Q, Kim JM, et al: Human ovarian
cancer and cisplatin resistance: possible role of inhibitor of
apoptosis proteins. Endocrinology. 142:370–380. 2001.PubMed/NCBI
|
|
63
|
Shah MA and Schwartz GK: Cell
cycle-mediated drug resistance: an emerging concept in cancer
therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
|
